Bionano Genomics (BNGO) Files DEF 14A for April 2 Meeting

Bionano Genomics (BNGO) has filed its DEF 14A proxy statement in preparation for its upcoming shareholder meeting on April 2. This document outlines important details regarding the proposals to be considered by shareholders at the meeting. The filing is a necessary step for compliance with SEC regulations and provides transparency to investors regarding corporate governance matters. Additionally, this filing may influence shareholder voting outcomes and related stock performance leading up to the meeting date.